{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"26.2","value":"70.2"},{"groupId":"OG001","spread":"25.7","value":"138"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"246"},{"groupId":"OG001","value":"245"}],"units":"Participants"}],"dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Baricitinib 2 mg PO QD through week 24.\n\nParticipants will continue to take background cDMARD therapy throughout study.","id":"OG000","title":"Baricitinib 2 mg"},{"description":"Baricitinib 4 mg PO QD through week 24.\n\nParticipants will continue to take background cDMARD therapy throughout study.","id":"OG001","title":"Baricitinib 4 mg"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"All randomized participants who received at least 1 dose of study drug with evaluable PK data.","reportingStatus":"POSTED","timeFrame":"Week 0: 30 and 90 minutes postdose; Week 8: 1 hour postdose; Week 12, Week 20 and Week 24:predose","title":"Population Pharmacokinetics (PK): Maximum Concentration at Steady State of Dosing (Cmax,ss) of LY3009104","type":"SECONDARY","unitOfMeasure":"nanogram per milliliter (ng/mL)"}